Latest / Glaucoma, Vision & Longevity: Supplements & Science / Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target?

Transcript

Scientists Protected Glaucoma Nerve Cells Without Lowering Eye Pressure — Could Mitochondria Become the Next Treatment Target? · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Scientists protected glaucoma nerve cells without lowering eye pressure.
• 0:04
  SPEAKER_00: Could mitochondria become the next treatment target?
• 0:07
  SPEAKER_00: Short answer: possibly, but the new study is a promising prevention result, not yet proof that mitochondrial treatment can restore vision after glaucoma damage is established.
• 0:19
  SPEAKER_00: The study at the center of this question was first published in Advanced Science on October 18, 2026.
• 0:26
  SPEAKER_00: Researchers used adeno-associated virus serotype 2 to increase akinase anchoring protein 1, or ACAP-1, in the retina.
• 0:35
  SPEAKER_00: Treated mice retained more retinal ganglion cells, had better electrical responses, and showed stronger tracer labeling along the projection to the brain, even while their eye pressure remained elevated.
• 0:46
  SPEAKER_00: The results support the idea of pressure-independent neuroprotection.
• 0:51
  SPEAKER_00: They do not show that treatment lowered pressure, nor do they show that it rescued neurons after damage was already measurable.
• 0:59
  SPEAKER_00: The October 2026 Advanced Science Paper.
• 1:02
  SPEAKER_00: That distinction matters.
• 1:05
  SPEAKER_00: A treatment given before pressure injury may prevent cells from becoming dysfunctional or dying.
• 1:10
  SPEAKER_00: A treatment given after visual function has declined would have to do something more: restore function in living but impaired cells, rebuild lost connections, or both.
• 1:20
  SPEAKER_00: The study did not test that harder question.
• 1:23
  SPEAKER_00: What ACAP1 does, ACAP1 is a signaling scaffold, a protein that helps hold other signaling proteins in a useful place.
• 1:31
  SPEAKER_00: It is normally attached to the outer membrane of mitochondria, the cell's energy-producing structures.
• 1:37
  SPEAKER_00: ACAP1 is not itself an energy-producing enzyme.
• 1:41
  SPEAKER_00: Its importance is that it helps organize signals near the mitochondrion, where those signals can influence mitochondrial shape, stress responses, and survival.
• 1:50
  SPEAKER_00: One important partner is protein kinase A, or PKA.
• 1:54
  SPEAKER_00: ACAP1 can anchor PKA close to mitochondrial targets, including the fission protein DRP1.
• 2:00
  SPEAKER_00: PKA-mediated phosphorylation of DRP1 at a particular site, serine 637 in the mouse numbering used in this work, usually makes DRP1 less able to drive mitochondrial fission.
• 2:11
  SPEAKER_00: The calcium-sensitive enzyme calcinurin can remove that phosphate, which can favor DRP1 activity and mitochondrial division.
• 2:19
  SPEAKER_00: Earlier laboratory work found that loss of ACAP1 in mouse retina was associated with lower DRP1 phosphorylation, more fragmented mitochondria, abnormal respiratory chain proteins, and signs of oxidative and cell death stress.
• 2:34
  SPEAKER_00: The earlier retinal ECAP1 study, mitochondria need both fusion and fission.
• 2:39
  SPEAKER_00: Fusion can help mitochondria share contents and maintain function.
• 2:43
  SPEAKER_00: Fission helps separate damaged parts, support mitochondrial transport, and allow quality control processes such as mitophagy.
• 2:51
  SPEAKER_00: The goal is not simply more fusion, it is a healthy balance that changes appropriately with a cell's needs.
• 2:58
  SPEAKER_00: ACAP1 is also linked to OPA1, a protein on the inner mitochondrial membrane that helps govern fusion and the structure of the folds called CRISTAe.
• 3:07
  SPEAKER_00: But the new study did not show that ACAP1 physically binds OPA1.
• 3:12
  SPEAKER_00: It showed that OPA1 levels changed along with ACAP1 treatment.
• 3:16
  SPEAKER_00: The direct mechanistic case is stronger for the ACAP1-PKA DRP1 relationship than for any direct ACAP1-OPA1 interaction.
• 3:25
  SPEAKER_00: Mitochondria also helped manage cellular calcium and supply energy for processes such as nerve signaling and the release of neurotransmitters.
• 3:33
  SPEAKER_00: It is therefore biologically plausible that mitochondrial stress could affect both calcium-sensitive signaling and synaptic performance.
• 3:42
  SPEAKER_00: But in the new study, calcium handling was not directly measured, and the investigators did not establish that ACAP1's synaptic effects were caused by restoring a particular calcium pathway.
• 3:54
  SPEAKER_00: The authors themselves note that they did not measure PKA catalytic activity, recruitment of PKA to mitochondria, or formation of the ACAP1 pKa complex.
• 4:04
  SPEAKER_00: Is ACAP1 reduced in people with glaucoma?
• 4:06
  SPEAKER_00: Not in the new October 2026 study.
• 4:09
  SPEAKER_00: That study is based on mouse models and cultured retinal cells, not human donor retina.
• 4:15
  SPEAKER_00: Its central experiments do not establish how ACAP1 changes in human glaucoma.
• 4:20
  SPEAKER_00: There is, however, relevant human tissue evidence in a separate study.
• 4:24
  SPEAKER_00: In a small postmortem series, ACAP1 staining was lower within retinal ganglion cell bodies from glaucoma donors.
• 4:32
  SPEAKER_00: The overall retinal signal was not simply lower.
• 4:35
  SPEAKER_00: A CAP1 staining was higher in some broader retinal measurements, apparently because ACAP1 was also increased in Miller glial cells.
• 4:43
  SPEAKER_00: In other words, the answer depends on which cell type and which retinal region are measured.
• 4:48
  SPEAKER_00: The human evidence is encouraging, but it is small, cross-sectional, and cannot tell whether the ACAP1 change caused degeneration or occurred in response to it.
• 4:58
  SPEAKER_00: Related study including human donor retina.
• 5:01
  SPEAKER_00: Fact, a separate small human tissue study reports lower ACAP1 signal in glaucoma retinal ganglion cell bodies.
• 5:09
  SPEAKER_00: Strong inference.
• 5:10
  SPEAKER_00: A cap 1 may be relevant to human disease, but it is not yet established as a consistently reduced causal driver across glaucoma patients.
• 5:19
  SPEAKER_00: What the October 2026 study actually did, the researchers used two mouse models and a set of cell culture experiments.
• 5:27
  SPEAKER_00: The treatment was a viral vector carrying mouse ACAP1 under a broad cytomegalovirus promoter.
• 5:33
  SPEAKER_00: The vector was not restricted to retinal ganglion cells.
• 5:36
  SPEAKER_00: Other retinal cells could also receive it.
• 5:39
  SPEAKER_00: DBA2J spontaneous glaucoma, DBA2J mice develop glaucoma as they age.
• 5:45
  SPEAKER_00: The researchers injected the vector into the vitreous of five-month-old mice and assessed them at 10 months.
• 5:51
  SPEAKER_00: Age-matched DBA2J GPNMB positive mice, which do not develop the same glaucoma phenotype, served as non-glaucomatous controls.
• 6:00
  SPEAKER_00: Only DBA2J mice with recorded intraocular pressure between 20 and 35 mm of mercury were included in the glaucoma analyses.
• 6:09
  SPEAKER_00: Across the screening cohort, 64 of 98 10-month-old DBA2J mice had confirmed pressure elevation.
• 6:16
  SPEAKER_00: The methods report peak pressure averages of 21.5-4.5 mm of mercury in right eyes and 19.93.7 mm of mercury in left eyes for the glaucoma mouse cohort.
• 6:29
  SPEAKER_00: These are not presented as the treatment versus control means for the specific vector comparison.
• 6:35
  SPEAKER_00: The authors report that ACAT-1-treated DBA2J mice had more retinal ganglion cells in both middle and peripheral retinal regions than glaucoma mice given the null vector.
• 6:46
  SPEAKER_00: More cholerotoxin B tracer labeling in the superior colliculus, a brain region receiving retinal input, higher pattern electroretinogram, and pattern visual evoke potential amplitudes, no improvement in pattern visual evoke potential latency.
• 7:01
  SPEAKER_00: The vector increased retinal ACAT-1 and also increased pKa abundance.
• 7:06
  SPEAKER_00: The paper reports the main outcomes as statistically significant, but the searchable article text does not give exact group means or percentage improvements for the plots.
• 7:17
  SPEAKER_00: The figure legends supply sample sizes, 20 mice per group for the pressure panel, 9 to 18 retinas or mice for retinal ganglion cell counts, 10 mice per group for electrical responses, and 3 mice for the superior colliculous tracer analysis.
• 7:33
  SPEAKER_00: Microbead-induced ocular hypertension.
• 7:36
  SPEAKER_00: In the second model, beads were placed in the front of the eye to obstruct fluid outflow and raise pressure.
• 7:42
  SPEAKER_00: The article's results section describes vector injection in three-month-old mice three weeks before the bead injection.
• 7:50
  SPEAKER_00: The methods section, however, describes six-week-old mice being injected with vector before bead administration.
• 7:57
  SPEAKER_00: This age discrepancy is an internal reporting inconsistency.
• 8:01
  SPEAKER_00: It does not change the key timing point.
• 8:04
  SPEAKER_00: The vector was given before ocular hypertension was induced.
• 8:08
  SPEAKER_00: The bead model produced sustained intraocular pressure in the reported range of 20 to 30 millimeters of mercury for at least eight weeks.
• 8:16
  SPEAKER_00: Pressure monitoring did not show a statistically significant difference between ACAP1 vector and nullvector groups.
• 8:24
  SPEAKER_00: Compared with nullvector mice, ACAP 1 treated mice retained more retinal ganglion cells, had better pattern electroretinogram and pattern visual evoked potential amplitudes, and had shorter, more normalized pattern visual evoked potential latency.
• 8:40
  SPEAKER_00: The figure legend reports 12 to 14 mice per group for pressure monitoring and electrical responses, and 7 to 10 retinal hole mounts per group for retinal ganglion cell counts.
• 8:51
  SPEAKER_00: The researchers also tested pressure-stressed retinal ganglion cells in culture.
• 8:56
  SPEAKER_00: Cells were transduced with the vector before exposure to elevated hydrostatic pressure or paraquat, an oxidative stressor.
• 9:04
  SPEAKER_00: ACAT-1 improved cell viability and oxygen consumption measures under stress.
• 9:09
  SPEAKER_00: This is useful mechanistic support, but it is another pre-injury treatment experiment, not a rescue experiment.
• 9:16
  SPEAKER_00: What the paper does and does not quantify.
• 9:20
  SPEAKER_00: The paper reports terms on statistical significance for many plotted outcomes, but the full text prose and figure legends do not provide exact numerical means, standard deviations, or percentage changes for most of the outcomes listed below.
• 9:34
  SPEAKER_00: I have not inferred precise bar heights from figures or invented values.
• 9:38
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 9:43
  SPEAKER_00: The full study gives the sample sizes and qualitative results, but not an accessible numeric table of all plotted outcome values.
• 9:52
  SPEAKER_00: That limits independent estimation of effect size and clinical relevance.
• 9:57
  SPEAKER_00: The article also reports that some ultrastructural analyses counted many mitochondria or synaptic structures, but drew those structures from only two mice per group.
• 10:07
  SPEAKER_00: Such measurements are informative for cell biology, but the number of mitochondria is not a substitute for the number of independent animals.
• 10:15
  SPEAKER_00: How convincing is the evidence for pressure-independent protection?
• 10:20
  SPEAKER_00: It is a meaningful preclinical result.
• 10:23
  SPEAKER_00: But pressure independent should be read as the observed protection was not accompanied by a detected pressure reduction, not as proof that every aspect of pressure exposure was perfectly matched.
• 10:35
  SPEAKER_00: The case is strengthened by three features.
• 10:37
  SPEAKER_00: Two different glaucoma models showed better retinal ganglion cell survival or visual responses with ACAP1 treatment.
• 10:45
  SPEAKER_00: In the microbead model, pressure was monitored and was reported as not significantly different between the ACAP1 and null vector treatment groups.
• 10:54
  SPEAKER_00: In the DBA2J model, glaucoma mice were selected from a pressure-elevated range, and the paper does not report pressure lowering by the vector.
• 11:04
  SPEAKER_00: But important qualifications remain.
• 11:06
  SPEAKER_00: A non-significant difference is not the same as proof of equivalent pressure exposure.
• 11:11
  SPEAKER_00: The study does not establish equivalence using a pre-specified equivalence margin.
• 11:16
  SPEAKER_00: Repeated pressure measurements are more informative than a single reading, but the paper does not demonstrate a complete high-resolution comparison of each eye's cumulative pressure burden, including nighttime or short-lived peaks.
• 11:30
  SPEAKER_00: In the DBA2J experiment, the reported pressure range is an inclusion criterion.
• 11:36
  SPEAKER_00: The paper does not provide detailed cumulative pressure exposure for each treatment group.
• 11:42
  SPEAKER_00: The study's separate ACAT-1 deficient mouse experiment is less clean as causal evidence.
• 11:48
  SPEAKER_00: Those mice had slightly higher pressure than wild type mice, and the authors acknowledge that this could have contributed to worse pattern electroretinogram responses.
• 11:57
  SPEAKER_00: Were the investigators blinded and were the samples large enough?
• 12:02
  SPEAKER_00: The animals were randomly assigned to experimental and control groups.
• 12:07
  SPEAKER_00: The paper explicitly says that sampling, segmentation, and quantification of the serial block face electron microscopy data were blinded.
• 12:15
  SPEAKER_00: In the accessible report, I did not find a comparable clear statement that the pressure measurements, electrical response assessments, retinal ganglion cell counts, or other key outcomes were blinded.
• 12:27
  SPEAKER_00: That is a reporting gap.
• 12:29
  SPEAKER_00: It does not prove that those assessments were unblinded.
• 12:32
  SPEAKER_00: The sample sizes are reasonable for an initial mouse study, but uneven in strength.
• 12:38
  SPEAKER_00: Pressure and electrical response groups often included around 10 to 14 animals, while many biochemical measures used only 3 to 8.
• 12:46
  SPEAKER_00: Some ultrastructural conclusions used two animals per group.
• 12:49
  SPEAKER_00: The study is also from one research program, and the two mouse models do not replace replication by independent laboratories or testing in a large animal.
• 12:59
  SPEAKER_00: Strong inference.
• 13:00
  SPEAKER_00: The study supports the conclusion that AKP1 can protect the retina without an observed reduction in pressure.
• 13:07
  SPEAKER_00: Fact.
• 13:08
  SPEAKER_00: It does not prove that cumulative pressure exposure was identical in every treated and untreated animal, and it does not provide human efficacy evidence.
• 13:17
  SPEAKER_00: Which parts of the proposed mechanism were demonstrated?
• 13:20
  SPEAKER_00: The proposed chain is elevated pressure, mitochondrial stress, lower ACAP1, abnormal DRP1 activity and fission, weaker energy production, synaptic dysfunction, inflammation and complement activation, retinal ganglion cell dysfunction and death.
• 13:36
  SPEAKER_00: The new study supports portions of this chain, but it does not demonstrate every arrow.
• 13:41
  SPEAKER_00: Elevated pressure and ACAP1.
• 13:44
  SPEAKER_00: The DBA2J glaucoma model showed lower retinal ACAP1 alongside pressure elevation and injury.
• 13:50
  SPEAKER_00: The microbed model and stressed cell experiments support a relationship between glaucomatous stress and retinal vulnerability.
• 13:58
  SPEAKER_00: But the experiments do not show that pressure directly lowers ACAP1 by one isolated mechanism, or that all the subsequent changes are caused by ACAP1 loss.
• 14:07
  SPEAKER_00: Evidence grade association in vivo, not a complete cause and effect test.
• 14:12
  SPEAKER_00: ACAP1, DRP1, and mitochondrial dynamics.
• 14:16
  SPEAKER_00: With ACAP1 restoration, the authors found higher DRP1 phosphorylation at serine 637, lower total DRP1, and no detectable change in phosphorylation at serine 616.
• 14:29
  SPEAKER_00: They also found more OPA-1, including more of its long form, while mitofusin 1 and mitochusin 2 protein levels were not changed.
• 14:38
  SPEAKER_00: These findings are consistent with a shift away from excessive fission and toward mitochondrial stability.
• 14:43
  SPEAKER_00: In pressure-stressed cultured retinal ganglion cells, ACAP1 also improved respiration and mitochondrial shape.
• 14:50
  SPEAKER_00: However, the study did not use a DRP-1 mutant that could no longer be phosphorylated at the relevant site, or an ACAP1 version unable to anchor pKa.
• 15:00
  SPEAKER_00: It therefore does not establish that DRP-1 phosphorylation is required for ACAP1's protective effect.
• 15:06
  SPEAKER_00: Evidence grade, strong preclinical support for a relationship, incomplete proof of the precise causal route.
• 15:13
  SPEAKER_00: Energy production and oxidative stress.
• 15:16
  SPEAKER_00: In cultured cells, ACAP1 improved basal, maximal, and adenosine triphosphate-linked oxygen consumption under pressure stress.
• 15:24
  SPEAKER_00: Under paraquat stress, it reduced mitochondrial superoxide.
• 15:28
  SPEAKER_00: In retina, it changed respiratory chain protein levels and stress-associated markers.
• 15:33
  SPEAKER_00: But the study's estimate of adenosine triphosphate production in some analyses came from a model using mitochondrial ultrastructure.
• 15:41
  SPEAKER_00: It was not a direct in vivo measurement of energy supply to retinal ganglion cells.
• 15:46
  SPEAKER_00: Evidence grade, direct respiratory measurements in cultured cells, indirect or proxy measures for several in vivo energy claims.
• 15:54
  SPEAKER_00: Synaptic changes in inflammation.
• 15:56
  SPEAKER_00: The paper found lower phosphorylation of calcium calmodulin-dependent kinase 2 and synapsin after ACAT-1 treatment, preservation of synaptophacin, and improved postsynaptic density protein 95.
• 16:08
  SPEAKER_00: It also found lower C1Q, IBA1, gliofibrillary acidic protein, and inflammatory transcripts in treated retina.
• 16:16
  SPEAKER_00: These are important observations, but they are associations.
• 16:20
  SPEAKER_00: The study did not show that changing C1Q or the synaptic proteins was necessary for the retinal ganglion cell benefit.
• 16:27
  SPEAKER_00: The authors also acknowledged that lower inflammatory markers could be a consequence of less retinal injury rather than a direct anti-inflammatory effect of ACAP-1.
• 16:38
  SPEAKER_00: Retinal ganglion cell function and death?
• 16:41
  SPEAKER_00: The researchers measured retinal ganglion cell counts and electrical responses.
• 16:45
  SPEAKER_00: Treatment groups did better than null vector groups at the study endpoints.
• 16:50
  SPEAKER_00: But because the animals were treated before ocular hypertension or before established DBA2J disease was documented, the experiments show preservation, not recovery, of already lost neurons.
• 17:02
  SPEAKER_00: Could surviving retinal ganglion cells be dysfunctional before they die?
• 17:06
  SPEAKER_00: Yes.
• 17:07
  SPEAKER_00: That is a plausible and increasingly important view of glaucoma.
• 17:11
  SPEAKER_00: Visual field loss does not require every affected retinal ganglion cell to have disappeared.
• 17:17
  SPEAKER_00: A surviving cell may be present but have impaired energy supply, damaged dendrites, disrupted synapses, or a failing connection to the brain.
• 17:26
  SPEAKER_00: The October study gives two pieces of evidence consistent with this idea.
• 17:30
  SPEAKER_00: In the ACAP1 deficient mice, exposed to ocular hypertension, pattern electroretinogram amplitude was worse even though retinal ganglion cell counts were not significantly lower than in pressure-stressed wild-type mice.
• 17:43
  SPEAKER_00: In DBA2J glaucoma, ACAC1 treatment improved electrical responses alongside structural protection.
• 17:50
  SPEAKER_00: The first finding is suggestive, not definitive.
• 17:54
  SPEAKER_00: The knockout animals had a small but statistically significant pressure difference, and the retinal cell count analysis may not have been powered to detect a modest additional loss.
• 18:04
  SPEAKER_00: The authors also note that lifelong ACAT-1 deficiency could prompt developmental compensation.
• 18:10
  SPEAKER_00: This fits a broader concept of functional reserve.
• 18:14
  SPEAKER_00: An eye can have more dysfunction than the number of visibly lost cells alone would predict.
• 18:19
  SPEAKER_00: Mitochondrial dysfunction could contribute to that reserve by leaving living neurons short of energy or less able to sustain synaptic signaling.
• 18:28
  SPEAKER_00: But this study did not determine what fraction of human visual field loss is reversible mitochondrial dysfunction rather than irreversible loss of cells and axons.
• 18:37
  SPEAKER_00: Could mitochondrial treatment restore function?
• 18:41
  SPEAKER_00: It is biologically plausible that improving energy supply might improve the performance of stressed but living retinal ganglion cells.
• 18:49
  SPEAKER_00: That possibility is different from regenerating dead cells, restoring lost optic nerve axons, or rebuilding disconnected brain circuits.
• 18:58
  SPEAKER_00: The study does not show that ACAT-1 restored existing synaptic function.
• 19:03
  SPEAKER_00: It measured better endpoint responses in animals treated before pressure injury.
• 19:07
  SPEAKER_00: There was no documented stage in which animals first developed impaired visual responses and were then treated.
• 19:14
  SPEAKER_00: Thus, function improved in the treated groups should be read as better function than in untreated glaucoma controls, not as proven recovery from a known pretreatment deficit.
• 19:24
  SPEAKER_00: Did the experiments test treatment after glaucoma was established?
• 19:29
  SPEAKER_00: No.
• 19:29
  SPEAKER_00: The main intervention experiments were preventive or early intervention designs.
• 19:34
  SPEAKER_00: DBES2J mice, the vector was injected at five months, while the model's pressure elevation typically begins around five to seven months and damage becomes marked later.
• 19:45
  SPEAKER_00: The study assessed the animals at 10 months.
• 19:48
  SPEAKER_00: The treatment was therefore given before advanced disease and may have preceded measurable injury in many animals.
• 19:55
  SPEAKER_00: Microbead model, vector was given three weeks before bead-induced pressure elevation.
• 20:01
  SPEAKER_00: Cell cultures, cells were transduced before exposure to pressure or paraquat stress.
• 20:07
  SPEAKER_00: The study did not test ACAP-1 restoration after documented retinal ganglion cell dysfunction, after measured cell loss, or after loss of axonal transport.
• 20:17
  SPEAKER_00: It did not demonstrate axonal regrowth.
• 20:19
  SPEAKER_00: The authors measured cholerotoxin B labeling in the superior colliculus, which is a useful proxy for transport and projection integrity, but not proof of regenerated axons or restored functional synapses in the brain.
• 20:33
  SPEAKER_00: Practical implication ACAP1 currently looks more like a candidate for slowing or preventing deterioration than a proven way to recover vision in established glaucoma.
• 20:44
  SPEAKER_00: How viable is AAV2 delivery to human retinal ganglion cells?
• 20:48
  SPEAKER_00: Adeno-associated virus serotype 2 is a plausible delivery vehicle for retinal ganglion cells, and intravitrial gene delivery has been tested clinically in optic nerve disease.
• 20:59
  SPEAKER_00: But AAV2 is used in eye gene therapy does not mean that every intravitrial AAV2 construct will efficiently reach every human retinal ganglion cell.
• 21:08
  SPEAKER_00: Delivery depends on dose, vector design, the retinal surface barriers, and individual immune responses.
• 21:15
  SPEAKER_00: Pre-existing neutralizing antibodies can reduce transduction.
• 21:19
  SPEAKER_00: Intravitrial vectors can also trigger inflammation, and immune responses may become more likely as dose increases.
• 21:26
  SPEAKER_00: After an initial injection, the body may make antibodies that make another dose less effective.
• 21:32
  SPEAKER_00: Review of ocular adenoassociated virus delivery barriers.
• 21:36
  SPEAKER_00: Study of human immune responses after intravitreal AAV2.
• 21:39
  SPEAKER_00: The new ACAT1 experiment used a mouse vector carrying mouse AKHAT1 and a broad promoter.
• 21:46
  SPEAKER_00: It does not establish the best human dose, the best promoter, whether expression should be limited to retinal ganglion cells, or how long expression remains safe and effective.
• 21:56
  SPEAKER_00: The researchers also did not conduct long term follow up.
• 22:00
  SPEAKER_00: Sufficient to show how durable the protection would be.
• 22:03
  SPEAKER_00: Permanent overexpression deserves particular caution.
• 22:06
  SPEAKER_00: Mitochondrial fission has normal roles in transport, quality control, and removal of damaged mitochondria.
• 22:13
  SPEAKER_00: A strong, lifelong push toward fusion could conceivably interfere with those processes or with mitochondrial movement along long axons.
• 22:22
  SPEAKER_00: The study did not show that overexpression caused harm, but it also did not establish a safe long-term expression range.
• 22:29
  SPEAKER_00: A dose response study and prolonged safety monitoring are needed before more ACAP1 can be assumed to be better.
• 22:37
  SPEAKER_00: Could medicines target the same pathway?
• 22:40
  SPEAKER_00: Several of the options named in the prompt have some connection to energy metabolism, mitochondrial quality control, or neuronal survival that does not make them substitutes for ACAP1 restoration.
• 22:51
  SPEAKER_00: To claim that a drug acts like ACAP1, researchers would need to show that it changes the relevant pathway in retinal ganglion cells at an achievable retinal dose and improves meaningful glaucoma outcomes.
• 23:03
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 23:08
  SPEAKER_00: For example, DRP1 inhibition and DV1 have been investigated in experimental pressure injury, but that is preclinical evidence, not a clinically available glaucoma treatment.
• 23:19
  SPEAKER_00: Nicotinamide has moved further into human research.
• 23:23
  SPEAKER_00: Small studies have reported functional signals, and a phase 3 trial of nicotinamide and pyruvate was designed to test longer-term outcomes.
• 23:33
  SPEAKER_00: The American Glaucoma Society and American Academy of Ophthalmology have cautioned that high-dose nicotinamide should be limited to supervised clinical trials because of potential liver toxicity.
• 23:45
  SPEAKER_00: Preclinical DRP1 inhibition study, Phase III nicotinamide and pyruvate trial design, American Glaucoma Society and American Academy of Ophthalmology guidance.
• 23:55
  SPEAKER_00: Bottom line on medicines No currently established drug has been shown to reproduce the full ACAP1 pKa DRP1 OPA1 response in the human retina at a proven therapeutic exposure.
• 24:07
  SPEAKER_00: How ACAP 1 compares with other neuroprotective approaches.
• 24:11
  SPEAKER_00: These are not all the same kind of treatment.
• 24:13
  SPEAKER_00: Some aim to protect surviving cells, others aim to improve cell function or regrow axons.
• 24:19
  SPEAKER_00: The table separates human development maturity from biological promise.
• 24:23
  SPEAKER_00: For the full table, please open this article on VisualFieldtest.com.
• 24:28
  SPEAKER_00: ASP 2767 information from a stellus G01 Phase II trial record.
• 24:34
  SPEAKER_00: NT501 Phase 1 glaucoma study.
• 24:37
  SPEAKER_00: Life Biosciences October 8th ER100 Update.
• 24:40
  SPEAKER_00: POU2F2 Optic Nerve Crush Study.
• 24:43
  SPEAKER_00: NIH Summary of Calcium Calmodulin-dependent Kinase II Research.
• 24:46
  SPEAKER_00: Ranking by Human Development Maturity.
• 24:48
  SPEAKER_00: Nicotinamide has the broadest human research base among these approaches.
• 24:53
  SPEAKER_00: GRO1 and NT501 have phase 2 glaucoma studies.
• 24:57
  SPEAKER_00: ASP2767 is in early human development.
• 25:00
  SPEAKER_00: ER100 has early phase 1 observations.
• 25:04
  SPEAKER_00: AK1 restoration and POU2F2 remain preclinical for glaucoma.
• 25:09
  SPEAKER_00: Ranking by potential to restore damaged function.
• 25:12
  SPEAKER_00: ER-100 and nerve growth factor approaches are explicitly aimed at supporting or rejuvenating surviving cells.
• 25:18
  SPEAKER_00: AK1 has a credible energy and synapse rationale, but has not yet been tested after dysfunction begins.
• 25:25
  SPEAKER_00: Po2F2 is notable for axon regeneration results after optic nerve crush, but that is not the same as chronic human glaucoma.
• 25:33
  SPEAKER_00: None can restore retinal ganglion cells that have already died.
• 25:37
  SPEAKER_00: What experiment would show whether ACAT1 can rescue established glaucoma?
• 25:42
  SPEAKER_00: The most convincing next experiment would deliberately wait until each animal has documented functional decline before treatment.
• 25:50
  SPEAKER_00: Induce ocular hypertension in a glaucoma model.
• 25:53
  SPEAKER_00: Measure pressure repeatedly and record a baseline pattern electroretinogram, visual evoked potential, retinal nerve fiber structure, and retinal ganglion cell integrity.
• 26:03
  SPEAKER_00: Enroll only animals with a pre-specified measurable functional deficit before end-stage cell loss.
• 26:09
  SPEAKER_00: Randomize them to ACAP1 vector, null vector, and an appropriate sham or control group.
• 26:14
  SPEAKER_00: Blind investigators measuring pressure, visual function, structure, tracer transport, and tissue outcomes.
• 26:22
  SPEAKER_00: Match or model cumulative pressure exposure rather than relying only on a non-significant difference in average readings.
• 26:29
  SPEAKER_00: Follow the animals long enough to distinguish a temporary change from durable protection.
• 26:35
  SPEAKER_00: Directly measure mitochondrial respiration and cellular adenosine triphosphate where possible and test whether blocking the proposed DRP1 or PKA mechanism removes the benefit.
• 26:46
  SPEAKER_00: Include a second cohort treated after documented retinal ganglion cell loss to determine whether the therapy has any capacity beyond protecting remaining neurons.
• 26:57
  SPEAKER_00: The decisive result would be a sustained improvement from each animal's own impaired pretreatment baseline without a pressure reduction, accompanied by evidence that the same previously impaired retinal ganglion cells remain alive and function better.
• 27:12
  SPEAKER_00: If ACAP1 treated animals merely decline more slowly than controls, that would establish neuroprotection, not rescue.
• 27:20
  SPEAKER_00: Could mitochondrial treatments become a real pressure-independent therapy?
• 27:25
  SPEAKER_00: Fact, the October 2026 study shows that preventive ACAP-1 restoration protected retinal ganglion cells and visual risk measures in two mouse glaucoma models without a detected lowering of eye pressure.
• 27:38
  SPEAKER_00: It also links treatment with improved mitochondrial measures, synaptic markers, and lower inflammatory markers.
• 27:45
  SPEAKER_00: Strong inference.
• 27:47
  SPEAKER_00: Mitochondrial resilience is a credible pressure-independent treatment target.
• 27:51
  SPEAKER_00: It may help preserve both retinal ganglion cells and the function of cells that have not yet died.
• 27:56
  SPEAKER_00: It would complement, not replace, pressure-lowering treatment.
• 28:01
  SPEAKER_00: Inform speculation.
• 28:03
  SPEAKER_00: ACAP-1 is likely to be part of human glaucoma biology, but it is unlikely to be the only driver.
• 28:09
  SPEAKER_00: Its importance may vary between patients, stages of disease, and retinal cell types.
• 28:14
  SPEAKER_00: A treatment that works best early before major cell and axon loss seems more plausible than one that restores advanced disconnected visual pathways.
• 28:24
  SPEAKER_00: Estimated probabilities and timeline.
• 28:26
  SPEAKER_00: These are judgment-based estimates, not published clinical trial probabilities.
• 28:30
  SPEAKER_00: They are intended to make uncertainty explicit.
• 28:33
  SPEAKER_00: Probability ACAT1 is genuinely important in human glaucomatous neurodegeneration, about 70%.
• 28:40
  SPEAKER_00: The cell-specific human tissue signal and converging animal biology support relevance.
• 28:45
  SPEAKER_00: Small human samples and uncertain causality keep the estimate well below certainty.
• 28:50
  SPEAKER_00: Probability AAV2 ACAT1 works in a primate glaucoma model, about 50% for measurable target engagement plus at least one structural or functional benefit.
• 29:00
  SPEAKER_00: Mouse results and AAV experience help.
• 29:03
  SPEAKER_00: Species-specific delivery, dose, and immune response are major unknowns.
• 29:08
  SPEAKER_00: Probability this specific pathway enters a human trial, about 35 to 40% by 2035.
• 29:15
  SPEAKER_00: AAV retinal delivery is already a clinical modality, but this particular product still needs a suitable human construct, dose, safety studies, and large animal evidence.
• 29:25
  SPEAKER_00: Probability it produces clinically meaningful neuroprotection.
• 29:29
  SPEAKER_00: About 20% overall at this stage.
• 29:31
  SPEAKER_00: The chance would rise if primate studies replicated the effect, and human trials showed slower progression on reliable structural and functional measures.
• 29:40
  SPEAKER_00: Probability it recovers some function in stressed but surviving retinal ganglion cells.
• 29:46
  SPEAKER_00: About 30%.
• 29:47
  SPEAKER_00: The biology is plausible, and the mouse functional results are encouraging, but there is no treatment after dysfunction evidence yet.
• 29:55
  SPEAKER_00: Earliest plausible first human trial, 2030 to 2032.
• 30:00
  SPEAKER_00: Assuming a well-funded program and favorable large animal and toxicology results, a more ordinary path could take longer.
• 30:08
  SPEAKER_00: Earliest plausible clinical availability, around 2038 if development proceeds unusually quickly and trials succeed.
• 30:16
  SPEAKER_00: Availability in the early 2040s, or no approval at all, is more realistic than assuming a near-term treatment.
• 30:23
  SPEAKER_00: The figures are estimates, not a forecast based on a completed development plan.
• 30:28
  SPEAKER_00: The key near-term test is not another claim that mitochondria matter.
• 30:32
  SPEAKER_00: It is whether ACAP1 can rescue established dysfunction while pressure is carefully matched and long-term safety is monitored.
• 30:40
  SPEAKER_00: Could fixing mitochondria protect vision even when eye pressure is already low?
• 30:45
  SPEAKER_00: Possibly.
• 30:46
  SPEAKER_00: This study strengthens the case that protecting retinal energy systems could slow vision loss even when treatment does not lower eye pressure.
• 30:55
  SPEAKER_00: It does not yet show that ACAP1 can restore vision after established glaucoma damage, and it provides no basis for stopping pressure-lowering treatment.
• 31:04
  SPEAKER_00: For now, mitochondrial resilience is a promising research direction, not a proven treatment.
• 31:11
  SPEAKER_00: All links to sources are available in the text version of this article.
• 31:15
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 31:18
  SPEAKER_00: Thanks for listening.
• 31:20
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.